Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome

Core Insights - Ultragenyx Pharmaceutical (RARE) has resubmitted its biologics license application (BLA) to the FDA for accelerated approval of its gene therapy candidate UX111, aimed at treating Sanfilippo syndrome type A (MPS IIIA) [1][8] - The company’s shares have decreased by 44.6% over the past year, contrasting with a 15.2% increase in the industry [2] BLA Resubmission Details - The FDA issued a Complete Response Letter (CRL) in July 2025, requesting additional information regarding chemistry, manufacturing, and controls (CMC) elements, which were facility- and process-related issues not tied to product quality [3][10] - The resubmitted BLA addresses all CMC observations from the CRL and includes long-term data supporting neurological benefits, along with biomarker data in line with FDA agreements [4][11] Regulatory Timeline - A target action date from the FDA is expected within a month, with a review period of up to six months anticipated, aiming for a decision in the third quarter of 2026 [5][8] Clinical Data and Efficacy - The original BLA submission was supported by data from the phase I/II/III Transpher A study, which showed that UX111 treatment led to a significant reduction in heparan sulfate (HS) levels in cerebrospinal fluid (CSF) and improved long-term cognitive development [9][11] - The updated clinical data in the resubmission includes an additional year of patient follow-up, demonstrating durable treatment benefits and increasing separation from untreated outcomes [11] Disease Context - Sanfilippo syndrome type A is a rare, fatal lysosomal storage disorder affecting the central nervous system, with approximately 3,000 to 5,000 patients in commercially accessible areas and a median life expectancy of 15 years [14]